AstraZeneca Partnering Brochure 2009

partnering growth fostering shared SPBD AstraZeneca Partnering While exceptional internal research strength remains a hallmark of our success, AstraZeneca is actively seeking external opportunities to complement our existing capabilities. Your guide to AstraZeneca Partnering The purpose of this brochure is twofold. First, it provides you with a summary of our strategic partnering interests. These are priority areas where we are actively seeking external collaborations. Second, it provides you with all the contact information to facilitate discussions with key representatives from AstraZeneca. For specific therapeutic opportunities please see the identified contact information under the respective areas of partnering interests. Fostering shared growth Success is driven by people, and we take pride in having people that are open and responsive – the type of people that our partners want to work with. We believe that people and relationships ultimately determine the success of any partnership, and we are committed to being transparent and responsive with all of our collaborators. Section guide SPBD CVGI Neuro O&I R&I NO STA USBDI PHC USCD ISMO AZ Japan AZ China Strategic Planning & Business Development Cardiovascular & Gastrointestinal Neuroscience Oncology & Infection Respiratory & Inflammation New Opportunities Science & Technology Alliances US Business Development & Innovation Personalized Healthcare Corporate Business Development N. America International Sales & Marketing Organization AstraZeneca Japan AstraZeneca China Our commitment to externalization To AstraZeneca, externalization is not a short-term stopgap to backfill the pipeline. It is a long-term commitment to step up our access to the world of scientific innovation that resides outside our laboratories. In addition to traditional in-licensing opportunities, our externalization activities span acquisitions, risk sharing deals, spin-outs, equity stakes, divestments and out-licensing deals. Because no two deals are the same, we work with potential partners to structure deals through customized approaches that allow both partners to leverage unique capabilities and assets in order to achieve common goals. Contact information: For general licensing and business development inquiries please contact: Strategic Planning & Business Development Strategic Planning & Business Development (SPBD) supports the delivery of this key strategic priority through a globally integrated cross-business organization. www.astrazeneca.com/partnering Chris Yochim SPBD External Relations chris.yochim@astrazeneca.com For information about biologics-related partnering opportunities which are handled by MedImmune, our global biologics unit, please contact: Sun Park InfoBusDev@MedImmune.com John Goddard Senior Vice President, Strategic Planning & Business Development Ravi Venkataramani InfoBusDev@MedImmune.com Cardiovascular & Gastrointestinal AstraZeneca is committed to the development of novel therapies to lengthen lifespan and improve quality of life by reducing the risk, prevalence and impact of cardiovascular disease. We aim to build on our strong position, as a world leader in cardiovascular medicines backed by over 50 years’ experience, focusing on unmet patient needs in the areas of dyslipidemia, thrombosis, type 2 diabetes/obesity, atherosclerosis and atrial fibrillation. In Europe and North America combined, between 10% and 20% of adults suffer from gastroesophageal reflux disease (GERD). Around 40% of patients still suffer from GERD symptoms despite PPI treatment. We aim to maintain our leading position in gastroesophageal reflux disease (GERD) by focusing on life cycle initiatives for Nexium® to broaden its use, coupled with innovative research and development of new therapies for GERD beyond acid suppression. Atherosclerosis Ì Targets and/or compounds relevant to regression or slowing progression of atherosclerosis, in particular: − Reverse cholesterol transport (RCT) by increasing ApoA1, HDL or other relevant mechanism − Anti-inflammatory mechanisms − Adhesion molecule mechanisms − Parenteral treatments for high risk atherosclerosis patients (e.g. ApoA1 mimetics) − Treatments for improving macro/microvascular function Biochemical markers, imaging technologies and relevant animal models to: − Evaluate efficacy of potential anti-atherosclerosis drugs − Study vulnerable plaque CVGI Ì Thrombosis & hemostasis Ì Ì Anti-platelets − Compounds with decreased risk for bleeding and maintained/improved efficacy Bleeding disorders − Compounds (for parenteral or oral use) for effective and safe treatment of bleeding disorders Key areas of partnering interest Diabetes Other cardiovascular areas Ì Glucose lowering compounds with beneficial or neutral effect on CV risk factors − Insulin sensitizers with beneficial effects on microvascular disease, macro-vascular disease or body weight (excluding PPARs) − Compounds with effect on beta cell protection/ regeneration Step-change insulin and management − Non-injectable administration (e.g. oral, inhalation, nasal or transdermal) − Non-invasive glucose monitoring Diabetic complications Ì Effective and safe compounds (preferably in clinical phase) for treatment of atrial fibrillation Gastrointestinal Ì Treatments in gastroesophageal reflux disease other than acid secretion inhibition Ì Contact information: Anna Rosengren Main contact for incoming opportunities anna.rosengren@astrazeneca.com Ì Ì Ì Ì Obesity Novel mechanisms for weight loss/prevention of weight regain Early stage opportunities with proof of concept in pre-clinical models Compounds in clinical phase with good efficacy and safety profiles Magnus Björsne Pre-clinical magnus.bjorsne@astrazeneca.com Andy Yates Clinical andy.yates@astrazeneca.com Neuroscience AstraZeneca aims to be a leader in neuroscience research delivering a range of life-changing medicines in key areas of unmet medical need. We have significant research efforts in diseases related to the central nervous system (CNS). Our research in this field is focused on neurological diseases, especially Alzheimer’s disease and cognitive disorders, psychiatric disorders, pain and anesthesia. Analgesia Ì Key areas of partnering interest Psychiatry Ì Schizophrenia/bipolar disorder − Novel therapeutics targeting psychosis − Novel therapeutics targeting cognition − Next generation antipsychotics Depression/anxiety − Novel mechanisms targeting monotherapy − Novel mechanisms targeting adjunctive therapy Late-stage opportunities in other psychiatric conditions Ì Ì Ì Novel therapeutics for chronic pain (both neuropathic and nociceptive) with particular interest in: − Modulators of peripheral ion channels: − Novel channel targets and platform technologies − Voltage gated ion channel targets (TRPs) − VR1 antagonists − Sodium channel (NaV1.7, 1.8) blockers − Calcium channel modulation − Potassium channel modulation − NGF modulation − Bradykinin receptor (B1) antagonists − mPGES inhibitors − Novel diagnostic clinical tools − Novel biomarkers and genetic biomarkers − Therapies with clinical proof of concept − Novel biologic approaches, including monoclonal antibodies, peptides and RNA technologies Neuro Neurology Alzheimer’s disease – disease modifying treatments − Novel targets demonstrating proof of principle in pre-clinical models with particular interest in targets in amyloid production, transport, degradation and removal, e.g.: − Beta and gamma secretase inhibitors − Aggregation inhibitors − Degradation and transport approaches − Differentiated biologics − Novel targets in tau, e.g.: − Kinases affecting tau hyperphosphorylation − Tau aggregation mechanisms − Animal models to study tau Alzheimer’s disease and cognitive disorders – treatment of symptoms − Targets having shown clinical signals of effect on cognition/biomarkers of cognition Biomarkers for diagnosis in Alzheimer’s, e.g.: − Serum markers − Novel imaging approaches Contact information: Jit Patel Pre-clinical and technology jit.patel@astrazeneca.com Ì Donald Dwyer Psychiatry clinical/later stage donald.dwyer@astrazeneca.com Ì Hans Hultberg Neurology clinical/later stage hans.hultberg@astrazeneca.com Jeff Witcher Analgesia clinical/later stage jeff.witcher@astrazeneca.com Oncology & Infection Oncology AstraZeneca is committed to the development of novel approaches to cancer therapy. Our portfolio includes products in clinical development for a range of solid and hematological tumors including breast, prostate, lung, colorectal, pancreatic and thyroid cancers. Current research is directed towards the identification of novel mechanisms regulating tumor cell growth and the supporting tumor environment. Key areas of partnering interest AstraZeneca is interested in national, regional and global opportunities for small molecules and biologicals in all therapeutic classes (biologic opportunities should be forwarded to our MedImmune colleagues as detailed in the SPBD section of this brochure). We are seeking collaborations and product licensing deals as well as platform technology opportunities. The key criterion for anti-bacterial product licensing deals is novelty although we have an interest in conventional anti-bacterials if late phase and differentiated. Key criteria for anti-viral product licensing deals are novelty or those complimentary to in-house targets, particularly for RSV and HCV. We have an interest in therapies for other viruses if late phase and differentiated. Examples of recent deals in infection: Key areas of partnering interest We are interested in both global and regional opportunities, including Japan and emerging markets such as China. We are seeking collaborations, product licensing deals and also biomarker platform technology opportunities. AstraZeneca is particularly interested in partnering opportunities for the following biological effect areas: O&I Ì Ì Licensed CytoFab™ from Protherics for sepsis treatment Licensed the rights to Cubicin™ from Cubist for China and many other Asia-Pacific and MEA markets Ì Ì Ì Ì Growth factors/survival signaling Vascular modulation DNA repair inhibition Immune mediated killing Contact information: Campbell Wilson Pre-clinical – Oncology (product and technology opportunities) campbell.wilson@astrazeneca.com Other areas of interest Ì Cytotoxics differentiated on efficacy, tolerability and/or safety grounds from existing agents (with differentiation demonstrated by randomized controlled phase II or later trials) Particular targets of interest are smac / bcl-2 / TRAIL / IAP and JAK2, FGF(R), IGF1(R), JAK2, PTEN pathway and c-met / HGF Ì David Harrison Clinical – Oncology david.harrison@astrazeneca.com Infection AstraZeneca’s mission in infectious disease research is the discovery and development of first-in-class anti-bacterial and anti-viral agents. Our current core expertise is in serious hospital-based infections. Anti-bacterials: AstraZeneca now markets Merrem®, a leading injectable carbapenem anti-bacterial, and has a pipeline of products that will principally target this area. Anti-virals: Through the acquisition of Arrow Therapeutics and MedImmune, AstraZeneca has established a strong position in anti-viral therapy. Through MedImmune, we market Synagis® and FluMist®. John Gustofson Pre-clinical and clinical – Oncology john.gustofson@astrazeneca.com Sandie Revett Pre-clinical – Infection (product and technology opportunities) sandra.revett@astrazeneca.com Karen Gallant Clinical – Infection karen.gallant@astrazeneca.com Respiratory & Inflammation AstraZeneca has active research programs to create novel treatments for diseases of the lungs and airways, such as asthma, chronic obstructive pulmonary disease (COPD) and other less prevalent disorders. We are developing novel drugs that interfere with the underlying disease processes, and the improvement of existing medications and delivery devices to simplify disease management for the patient. New Opportunities The objective of the New Opportunities team is to deliver a successful portfolio of new treatment opportunities from areas outside our current therapy area focus. The team identifies, evaluates and secures new business opportunities that can deliver new medicines to patients and enhance the performance of AstraZeneca. Key areas of partnering interest Respiratory Differentiated treatments at phase III/Regulatory filing in a broad range of indications including opportunities for global, regional or individual market commercialization. Key areas of partnering interest Ì Ì Ì Ì Ì Ophthalmology Bone regeneration Wound healing Acute critical care Dermatology Ì COPD and asthma − Advanced clinical programs − Early stage alliances focused on: − Control of exacerbations – targets: inflammation, rhinovirus − Muscle dysfunction and CV complications of COPD − Facilitating lung recovery – targets: inflammation, mucus destruction, remodeling Novel inhalation approaches or other delivery concepts R&I/NO Ì Inflammation Novel treatments in other areas of inflammatory diseases. Ì Rheumatology − Agents in clinical development with patient efficacy data that are differentiated from marketed products, specifically in rheumatoid arthritis, systemic lupus erythematosus and scleroderma − Early stage alliances in rheumatology Contact information: Lena Mårtensson Pre-clinical lena.martensson@astrazeneca.com Contact information: Jenny Horsfield New Opportunities jenny.horsfield@astrazeneca.com Pontus Nilsson Clinical pontus.nilsson@astrazeneca.com Paul Fletcher New Opportunities paul.fletcher@astrazeneca.com Science & Technology Alliances AstraZeneca has created one of the most powerful and integrated global discovery engines in the pharmaceutical industry, and is continually improving its abilities to discover and develop new innovative medicines. To do this, we are seeking to access advances in new technologies and capabilities from the external community that can be applied to enhance the quality, effectiveness, and productivity of AstraZeneca R&D. The Science and Technology Alliances team works across therapeutic areas and functions to identify, evaluate and secure opportunities in key areas of technology interest to AstraZeneca. Key areas of partnering interest We are seeking collaborations and licensing opportunities aligned to key areas of technology interest including: Chemistry Ì Ì Ì Ì Ì Ì Ì Ì Expanding the scope of synthetic methodology Novel Lead Generation technologies Predictive QSAR methodology Membrane protein structure determination STA Predictive biology High content screening technologies for large scale compound profiling Physiological cell-based efficacy screening technologies (e.g. stem cell derived) Target validation methodology Improved methodology for safety/toxicity prediction e.g. − in-silico simulation − in-vitro predictive models − in-vivo imaging Contact information: Alan Lamont Science & Technology Alliances alan.lamont@astrazeneca.com Predictive medicine Ì Ì Ì In-silico disease simulation and prediction models Rapid sequencing technology for sample biomarker analysis Imaging technologies providing functional measurements of disease activity Knowledge management/informatics Ì Ì Structured searching and text mining tools Patent informatics Iain Comley Science & Technology Alliances iain.comley@astrazeneca.com US Business Development & Innovation AstraZeneca’s US Business Development & Innovation team leads the sourcing and evaluation of external opportunities to grow the US business. Key Areas of Partnering Interest Late stage pharmaceutical compounds Products in our therapeutic areas of interest that are nearing or in phase III development that can benefit from: Ì Ì Deep and rich clinical development support in seeking FDA approval Exceptional US sales and marketing capabilities Contact information: Diagnostics Tests, platforms or systems that screen, affirmatively diagnose, contribute to affirmative diagnosis, or predict risk. These may include: Adele Gulfo Vice President Ì Ì Ì Ì POC (point-of-care in physician offices and/or patient homes) Lab tests Molecular diagnostics Imaging Connie Fogarty Executive Director Preference for diagnostics that are FDA-approved/cleared or currently under FDA review that could benefit from additional US marketing and sales capabilities. Novel therapeutics Devices or device-systems – either invasive or non-invasive – used in conjunction with medication, that: Mahendra Gupta Cardiovascular/Metabolic, Oncology & Infection mahendra.gupta@astrazeneca.com USBDI Ì Ì Improve conditions and/or symptoms while contributing to significant improvement in quality of life using stimulation or other mechanism Help patients tolerate side effects from essential treatments Richard Skelly CNS & Chronic Pain richard.skelly@astrazeneca.com Novel therapeutics also includes unique breakthrough products that do not fit neatly into other areas, but do fit with AstraZeneca’s patient-focused mission. Preference for novel therapeutics that are FDA-approved/ cleared or currently under FDA review that could benefit from additional US marketing and sales capabilities. Earlier stage products may be considered if there is a strong strategic fit. David Arvan Respiratory, Inflammation & Gastroenterology david.arvan@astrazeneca.com Elizabeth Douglass Diagnostics & Novel Therapeutics elizabeth.douglass@astrazeneca.com Personalized Healthcare AstraZeneca recognizes the increasing potential and importance of science-driven patient selection strategies that offer the possibility of enhanced clinical benefit or improved safety profile for all therapeutic agents – Personalized Healthcare (PHC). Personalized Healthcare has become a fundamental component of drug discovery and development today, and AstraZeneca has taken positive steps to ensure that all novel drug development projects establish appropriate PHC strategy based on the current state of the science and clinical understanding. The cross-functional PHC Core Team identifies, evaluates and facilitates diagnostic partnerships for drug project teams implementing PHC strategies in all disease areas. Corporate Business Development North America The US-based SPBD team leads the externalization needs of the greater AZN community by leading the transaction process for global territory deals as well as territory-specific deals including the US. Supporting a wide range of customers and transaction types Ì Ì Ì Ensuring excellence in transaction execution for in-licenses, divestments and broad collaborations Supporting North American Leadership with product opportunities to strengthen the pipeline and portfolio Working within Global SPBD to provide for optimal resource deployment for dealmaking excellence Key areas of partnering interest The PHC Core Team is interested in diagnostic capabilities that are able to deliver clinically meaningful segmentation to patients, including methodologies for patient selection, disease identification or dosing. Diagnostic technologies of interest include but are not limited to: Ì Ì Ì Ì Ì Ì Ì Ì Ì Ì Genetic polymorphism/mutation detection (germline and somatic) DNA methylation Gene copy number, gene expression Microbiology Immunohistochemistry, immunoassays Protein detection, lipids Clinical chemistry, glucose monitoring Near-patient/point-of-care Clinical imaging Novel techniques Augustine Yee Corporate Business Development North America augustine.yee@astrazeneca.com Russ Gantt Vice President Contact information: PHC/USCD In addition, the PHC Core Team is interested in diagnostic partners who can provide capabilities in drug-diagnostic co-development, diagnostic regulatory submission, reimbursement, market access, and global delivery (lab service networks). Contact information: Cecilia Schott Personalized Healthcare cecilia.schott@astrazeneca.com Kathleen Dougherty Corporate Business Development North America kathleen.y.dougherty@astrazeneca.com Mahmood Ladha Corporate Business Development North America mahmood.ladha2@astrazeneca.com International Sales & Marketing Organization (ISMO) ISMO represents a very large organization geographically, covering all markets outside North America. ISMO Regions cover over 100 countries in Europe, Japan, Asia-Pacific, Latin America, Middle East and Africa. Key areas of partnering interest ISMO is interested in national and regional in-licensing opportunities for late stage, registered and marketed products. ISMO BD&L works alongside SPBD in assessing and evaluating products and multi-product opportunities for third party agreements covering product acquisitions, in-licensing, co-marketing, co-promotion and distribution agreements. We have extensive experience of national and regional partnerships and alliances, and have our own Alliance Management Group supporting existing deals. ISMO offers an excellent preferred partnership for high performance delivery at national, regional, and multi-regional levels. Capability & reach Ì Ì Ì Ì Cutting edge commercial programs, delivering industry-leading performance across all regions Global reach and critical mass in all key international markets High commitment to specialty and primary care target audiences Therapeutic focus and expertise in CV, GI, Respiratory, Oncology, Neuroscience and Infection Sales & marketing strength Ì Ì Ì Unrivaled capacity to launch and optimize commercialization of brands across ISMO regions Outstanding sales and marketing performance with primary and secondary care brands, (Nexium®, CRESTOR®, Arimidex®, SEROQUEL® and Symbicort®) AstraZeneca outperformed the pharmaceutical markets in Latin America, Asia-Pacific, Middle East and Africa in 2007 and was the fastest growing Top10 MNC across emerging markets AstraZeneca has more than doubled its business in emerging markets over the last five years reaching US$ 3.2bn in 2007 AstraZeneca has an R&D facility in Bangalore, India working on TB and other developing world diseases AstraZeneca owns manufacturing facilities in emerging markets, e.g. Cairo, Egypt All commercial programs have been rolled out in all emerging territories Ì Ì Ì Ì Contact information: ISMO Len Holmes len.holmes@astrazeneca.com Jeanette Evans jeanette.evans@astrazeneca.com AstraZeneca Japan AstraZeneca highly values the discovery research and drug development activities being performed in Japan. Through strategic alliances, licensing and R&D collaborations, AstraZeneca in Japan develops innovative drugs, thereby helping to improve people’s lives globally. Our representatives in Japan act as contacts for the following alliance activities, and we are also seeking in-licensing opportunities (especially oncology) for the Japanese territory. Key areas of partnering interest Ì Pharmaceutical and biotechnology companies − Research collaborations for discovery − Licensing compounds and products (global and/or Japan) − Technology transfer Academia − Research collaborations for discovery − Technology transfer Ì Contact information: For your first contact, please submit an e-mail to biotech.transfer.japan@astrazeneca.com Iku Sugioka Licensing compounds and products iku.sugioka@astrazeneca.com Masaki Nakanishi Licensing compounds and products masaki.nakanishi@astrazeneca.com Motonori Yamaguchi Research collaborations and technology transfer motonori.yamaguchi@astrazeneca.com AZ Japan Akiko Matsumoto Research collaborations and technology transfer akiko.matsumoto2@astrazeneca.com akiko.matsumoto2@astrazeneca.com AstraZeneca China AstraZeneca recognizes the rapid development of science and innovation in China related to discovery research and drug development, and we have a brand new R&D center in Shanghai. We are actively seeking strategic alliance opportunities and R&D collaborations with Chinese academia as well as pharmaceutical and biotechnology companies. Key areas of partnering interest Ì Ì Ì CNS, pain, oncology, respiratory, inflammation, diabetes, obesity, atherosclerosis, serious bacterial and fungal infection, and special viral infections (e.g. RSV, HBV, HCV) Chemistry, protein biochemistry, predictive toxicology and other skill and technology areas relevant for pharmaceutical R&D Late stage or in-market products from companies that are under-leveraged in China Contact information: Richard Wang Global Discovery Research in China AstraZeneca Innovation Centre China richard.wang@astrazeneca.com AZ China AstraZeneca is engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and in the supply of healthcare services. AstraZeneca is one of the world’s leading pharmaceutical companies with global healthcare sales of $31.6 billion, and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. We are active in over 100 countries with a total workforce of over 65,000 with growing presence in important emerging markets. Within R&D we employ around 12,000 people at 17 research and development centres in 8 countries. www.astrazeneca.com/partnering